The RLR family members, RIG-I and MDA5, functioning as intracellular pattern recognition receptors, are gaining prominence as potential therapeutic targets in cancer due to their capacity to engage with mislocalized mtRNA and other innate RNAs, thus triggering potent immune responses [187]. The gene discussed is DHX58; the disease is cancer.